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Spironolactone and 
proteinuria
Increasing evidence has shown that 
blockade of aldosterone receptors is 
benefi cial in congestive heart failure, 
even in patients who are treated with 
angiotensin antagonists. In this issue, 
Bianchi et al. present interesting 
studies on patients with chronic kidney 
disease and proteinuria. Th e patients 
were treated with converting enzyme 
inhibitors and/or angiotensin receptor 
blockers and compared with those 
treated with added spironolactone. 
Initially, the two groups excreted about 
2 grams of protein a day. Aft er 1 year, 
protein excretion was reduced by 
more than 50% in the spironolactone-
treated patients. In both groups, 
blood pressure was reduced equally 
and glomerular fi ltration rate was 
not reduced signifi cantly. Th ere was a 
signifi cant correlation between the levels 
of proteinuria and aldosterone in both 
groups. As expected, the patients taking 
aldosterone antagonists had higher 
serum K levels.
While these results are interesting 
and represent a novel therapeutic 
addition to our armamentarium, they 
beg the question of what is the cause of 
the eff ect. Th e blood pressure in both 
groups was equally reduced, though 
not to optimal levels. Workers in the 
fi eld have mentioned an ‘aldosterone 
escape’ during converting enzyme 
inhibition. Whatever aldosterone escape 
means, the levels in the patients taking 
both converting enzyme inhibitors 
and receptor blockers were quite low. 
Mild hyperkalemia was found; could 
this be the cause of the eff ect? Many 
studies show excellent correlations 
between serum K intake and general 
cardiovascular health. Perhaps this 
is a mechanistically obscure salutary 
eff ect of high serum K. Whatever the 
mechanism, the results are suffi  ciently 
intriguing to make physicians think 
about the use of the aldosterone 
antagonists in their patients. See page 
2116. An excellent Commentary by 
Weinberger and Luft  (page 2051) 
discusses the wider context of the 
issues brought up in the paper.
Heparanase in 
diabetic nephropathy
Heparan sulfate proteoglycans are 
abundant in the kidney and present in 
the glomerular basement membrane, 
where they contribute negative charge. 
Th e presence of these charges restricts 
the fl ow of charged proteins, and 
experimental removal of the charge 
results in proteinuria. When van den 
Hoven et al. studied the expression of 
heparanase in diabetic nephropathy, 
they found that heparan sulfate was 
reduced in the glomeruli of such patients 
simultaneously, with an increase in 
expression of heparanase. Similarly, 
when rats or mice were made diabetic 
(by treatment with streptozotocin), 
they also overexpressed heparanase 
in their glomeruli. When mice were 
made to overexpress heparanase by 
transgenic means, the amount of 
heparan sulfate in their glomeruli was 
reduced. Importantly, these mice had 
proteinuria. Th ese studies provide a 
new idea that is worth pursuing in a 
variety of proteinuric kidney diseases. 
An important question remains: what 
is the proximate cause of induction of 
this enzyme by hyperglycemia or lack of 
insulin? See page 2100.
Inflammation and 
hemodialysis
Increasing evidence shows that 
infl ammation is a source of 
cardiovascular morbidity in a variety 
of diseases, such as atherosclerosis. 
In hemodialysis, the blood is exposed 
to a membrane that might activate 
white blood cells and lead to release 
of infl ammatory mediators. In newly 
published research, Friedrich et al. 
performed microarray studies on 
the leukocytes of patients, isolated 
before and aft er a 4-hour dialysis with 
a high-fl ux membrane. Th ey divided 
patients into two groups on the basis 
of their levels of C-reactive protein, a 
marker of infl ammation. Th ey found 
that several important infl ammatory 
cytokines, such as tumor necrosis 
factor-α and interleukin-8 and their 
receptors, were upregulated aft er 
dialysis. Th ere was also an increase 
in the levels of interleukin-10 and 
interferon-γ cytokines — thought to 
be anti-infl ammatory. Patients with 
low C-reactive proteins seemed to have 
a larger increase in these cytokines. 
Th ese studies show that routine 
hemodialysis has dramatic eff ects on 
the transcription of pro- and anti-
infl ammatory cytokines by leukocytes. 
How this will aff ect the general state of 
these patients remains to be shown in 
future studies. See page 2124.
